Society Needs Regulations to Prevent Research Abuses

Society Needs Regulations to Prevent Research Abuses

A tension exists between scientists/doctors and government regulators.

(© wladimir1804/Fotolia)


Keep Reading Keep Reading
Robert Klitzman
Robert Klitzman, MD, is a professor of psychiatry at the Vagelos College of Physicians and Surgeons and the Joseph Mailman School of Public Health, and the director of the Masters in Bioethics program at Columbia University. He has published over 130 scientific journal articles and eight books, including When Doctors Become Patients; A Year-Long Night: Tales of a Medical Internship; In a House of Dreams and Glass: Becoming a Psychiatrist; Being Positive: The Lives of Men and Women With HIV; The Trembling Mountain: A Personal Account of Kuru, Cannibals and Mad Cow Disease; Mortal Secrets: Truth and Lies in the Age of AIDS (with Ronald Bayer); Am I My Genes? Confronting Fate and Other Genetic Journeys; and The Ethics Police?: The Struggle to Make Human Research Safe. He has received numerous awards for his work, is a Distinguished Fellow of the American Psychiatric Association, a member of the Council on Foreign Relations, and a regular contributor to the New York Times and CNN.
Hidden figures: Five black women that changed science forever

Dr. May Edward Chinn, Kizzmekia Corbett, PhD., and Alice Ball, among others, have been behind some of the most important scientific work of the last century.


Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

natural killer cell
NIAID, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.

Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.